378 related articles for article (PubMed ID: 17692064)
1. Adalimumab vs. etanercept in psoriasis.
Downs AM
Clin Exp Dermatol; 2007 Sep; 32(5):593. PubMed ID: 17692064
[No Abstract] [Full Text] [Related]
2. The return of investment of translational research in inflammatory dermatoses.
van de Kerkhof PC
J Dermatolog Treat; 2008; 19(6):317. PubMed ID: 18982511
[No Abstract] [Full Text] [Related]
3. Switching from etanercept to adalimumab is effective and safe: results in 30 patients with psoriasis with primary failure, secondary failure or intolerance to etanercept.
Van Lümig PP; Lecluse LL; Driessen RJ; Spuls PI; Boezeman JB; van de Kerkhof PC; De Jong EM
Br J Dermatol; 2010 Oct; 163(4):838-46. PubMed ID: 20649798
[TBL] [Abstract][Full Text] [Related]
4. Switching to adalimumab in patients with moderate to severe psoriasis who have failed on etanercept: a retrospective case cohort study.
Woolf RT; Smith CH; Robertson K; Barker JN
Br J Dermatol; 2010 Oct; 163(4):889-92. PubMed ID: 20854408
[No Abstract] [Full Text] [Related]
5. Management of severe psoriasis with TNF antagonists. Adalimumab, etanercept and infliximab.
Mössner R; Reich K
Curr Probl Dermatol; 2009; 38():107-136. PubMed ID: 19710553
[TBL] [Abstract][Full Text] [Related]
6. Switching biologics for psoriasis.
Ormerod AD
Br J Dermatol; 2010 Oct; 163(4):667-9. PubMed ID: 20854399
[No Abstract] [Full Text] [Related]
7. [Biologics in the treatment of psoriasis].
Dissemond J; Grabbe S
MMW Fortschr Med; 2006 Sep; 148(38):42-4. PubMed ID: 17036963
[TBL] [Abstract][Full Text] [Related]
8. Paradoxical worsening of psoriasis when switching from etanercept to adalimumab: a case series.
Bhutani T; Koo J
J Dermatolog Treat; 2011 Apr; 22(2):75-8. PubMed ID: 20524874
[TBL] [Abstract][Full Text] [Related]
9. Newer treatment options for patients with moderate-to-severe psoriatic disease.
Roebuck HL
Nurse Pract; 2006 Aug; 31(8):5-6,11. PubMed ID: 16966969
[No Abstract] [Full Text] [Related]
10. [European and British recommendations on the role of biologic interventions in moderate to severe psoriasis].
Bachelez H; Battistella M
Ann Dermatol Venereol; 2011 Apr; 138(2 Suppl 2):H14-7. PubMed ID: 21703457
[No Abstract] [Full Text] [Related]
11. Anti-TNF-alpha therapy in childhood pustular psoriasis.
Pereira TM; Vieira AP; Fernandes JC; Antunes H; Basto AS
Dermatology; 2006; 213(4):350-2. PubMed ID: 17135745
[No Abstract] [Full Text] [Related]
12. Comparison of drug survival rates for adalimumab, etanercept and infliximab in patients with psoriasis vulgaris.
Gniadecki R; Kragballe K; Dam TN; Skov L
Br J Dermatol; 2011 May; 164(5):1091-6. PubMed ID: 21219290
[TBL] [Abstract][Full Text] [Related]
13. Advertisements for TNF Inhibitors.
Med Lett Drugs Ther; 2008 Nov; 50(1299):89. PubMed ID: 19008788
[No Abstract] [Full Text] [Related]
14. Experience with biologics for psoriasis in daily practice: switching is worth a try.
Lecluse LL; de Groot M; Bos JD; Spuls PI
Br J Dermatol; 2009 Oct; 161(4):948-51. PubMed ID: 19663876
[No Abstract] [Full Text] [Related]
15. Ustekinumab treats psoriasis refractory to seven conventional and biologic therapies.
Rallis E; Verros CD
Dermatol Online J; 2011 Apr; 17(4):14. PubMed ID: 21549089
[No Abstract] [Full Text] [Related]
16. A scientific debate: key clinical questions in the management of psoriasis.
Stingl G
J Eur Acad Dermatol Venereol; 2012 Aug; 26 Suppl 5():1. PubMed ID: 22758910
[No Abstract] [Full Text] [Related]
17. Recalcitrant cutaneous sarcoidosis responding to adalimumab but not to etanercept.
Field S; Regan AO; Sheahan K; Collins P
Clin Exp Dermatol; 2010 Oct; 35(7):795-6. PubMed ID: 20831604
[No Abstract] [Full Text] [Related]
18. Adalimumab treats psoriasis in patients previously treated with etanercept: a case series.
Yamauchi PS; Mau N
J Am Acad Dermatol; 2009 Jul; 61(1):158-60. PubMed ID: 19539861
[No Abstract] [Full Text] [Related]
19. Treatment of necrobiosis lipoidica with etanercept and adalimumab.
Zhang KS; Quan LT; Hsu S
Dermatol Online J; 2009 Dec; 15(12):12. PubMed ID: 20040262
[No Abstract] [Full Text] [Related]
20. [What is the impact of the new clinical trial data? What are the lessons for patient management?].
Passeron T; Boulinguez S
Ann Dermatol Venereol; 2010 May; 137(5 Suppl 1):11-5. PubMed ID: 20510174
[No Abstract] [Full Text] [Related]
[Next] [New Search]
